Success Metrics

Active Trials
6(86%)

Phase Distribution

Ph phase_1
6
86%
Ph phase_2
1
14%

Phase Distribution

6

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
6(85.7%)
Phase 2Efficacy & side effects
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

7

all time

Status Distribution
Active(7)

Detailed Status

Recruiting4
Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
6
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 16 (85.7%)
Phase 21 (14.3%)

Trials by Status

active_not_recruiting229%
not_yet_recruiting114%
recruiting457%

Recent Activity

6 active trials
Showing 5 of 7
not_yet_recruitingphase_1

Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL

NCT07847957
recruitingphase_1

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

NCT06887803
recruitingphase_1

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

NCT07203391
recruitingphase_1

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

NCT07018752
recruitingphase_1

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT06644183
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07847957Phase 1

Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL

Not Yet Recruiting
NCT06887803Phase 1

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

Recruiting
NCT07203391Phase 1

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Recruiting
NCT07018752Phase 1

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Recruiting
NCT06644183Phase 1

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Recruiting
NCT06879717Phase 1

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

Active Not Recruiting
NCT06717126Phase 2

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

Active Not Recruiting

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7